Allergic Conjunctivitis

Ocular Therapeutix and AffaMed Therapeutics have entered an agreement for the development and commercialization of Dextenza and OTX-TIC in areas of Asia, according to a press release.

The FDA has approved an investigational new drug application for the evaluation of VSJ-110, a cystic fibrosis transmembrane conductance regulator activator, for treating allergic conjunctivitis, according to a press release.

A retrospective study showed a statistically significant relationship between allergic conjunctivitis risk and sudden change in temperature, which can be compounded with a decline in humidity.

In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, Steven M. Silverstein, MD, discusses the results of a phase 3 study of Dextenza for the treatment of allergic conjunctivitis.

Following preliminary discussion with the FDA, Aldeyra Therapeutics plans to continue advancing reproxalap for dry eye disease, according to a company press release.

Dextenza demonstrated a statistically significant mean change in ocular itching scores from baseline in patients with allergic conjunctivitis, according to a press release from Ocular Therapeutix.

ATLANTA – Eyevance announced the U.S. launch of Zerviate, indicated for treating ocular itching associated with allergic conjunctivitis.

Eyevance Pharmaceuticals has launched Zerviate, a treatment for ocular itching related to allergic conjunctivitis, in the United States, according to a press release.

Aldeyra Therapeutics will prioritize its ocular disease programs while placing on hold clinical development in other fields as part of a strategic prioritization program, according to a press release.

Several physicians who spoke with Healio Primary Care applauded the FDA’s decision to make Pataday Twice Daily Relief and Pataday Once Daily Relief available over the counter to patients 2 years of age and older with itchy eyes associated with allergic conjunctivitis.